Home > Insider Trading > Filing (0000899243-19-015678)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1351288	Gw Pharmaceuticals Plc	GWPH	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1754163	J. Christopher Tovey	Sovereign House, Vision Park, Histon Cambridge X0 CB24 9BZ	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2019-06-03	64,800	$3.24	67,303	No	4	M	Direct
Ordinary Shares	Disposition	2019-06-03	64,800	$14.61	2,503	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Options	Disposition	2019-06-03	64,800	$0.00	64,800	$3.24

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2019-02-15	2026-02-15	No	4	M	Direct

Footnotes

Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer.
Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 3, 2019.
Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2019.
The price reported in Column 4 is a weighted average price per ordinary share ($175.35 per ADS). These shares were sold in multiple transactions at prices ranging from $175.04 per ADS (or $14.59 per ordinary share) to $175.64 per ADS (or $14.64 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.